Arrowhead Pharma (ARWR)

$72.69 -5.26 (-6.75%)
Market Cap 10.18B
Revenue (ttm) 829.45M
Net Income (ttm) -1.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -0.20%
Debt to Equity Ratio 0.36
Volume 2,700,200
Avg Vol 2,129,884
Day's Range N/A - N/A
Shares Out 140.03M
Stochastic %K 35%
Beta 1.28
Analysts Strong Sell
Price Target $84.54

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, t...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 304 3400
Fax: 626 304 3401
Address:
177 East Colorado Boulevard, Suite 700, Pasadena, United States
newarray
newarray May. 9 at 4:47 AM
$ARWR it's used to be 12% down-er I am glad mm can't shake more
0 · Reply
StockingStuffer2832
StockingStuffer2832 May. 8 at 8:20 PM
$ARWR probably under$70 for next weeks OpEx methinks. Got a lot of calls to knock out.
0 · Reply
skeezbag
skeezbag May. 8 at 5:26 PM
$ARWR mm just doing whatever they fucking want today. No consequences so wtf not
1 · Reply
Jblack500
Jblack500 May. 8 at 3:59 PM
$ANIP $GILD $ELAN $ARWR $ABVX who bought the dip..I know I did...current pt is near 110 and will see pt increases on this q and guidance
0 · Reply
stockhunter45
stockhunter45 May. 8 at 3:17 PM
$ARWR I think algos are dropping it on the earnings loss and once people with common sense understand at this point those numbers are not that significant this will go back up
0 · Reply
CDMO
CDMO May. 8 at 3:13 PM
$ARWR crazy swings
0 · Reply
Jblack500
Jblack500 May. 8 at 1:55 PM
$ANIP $GILD $ELAN $ARWR $ABVX anip pullback on these earnings is a gift and should be bought
0 · Reply
skeezbag
skeezbag May. 8 at 1:48 PM
$ARWR mm can go fuck themselves. This was set up yesterday with the bogus AH bid ask
0 · Reply
BiodegradableBurger
BiodegradableBurger May. 8 at 12:57 PM
$ARWR Wtf is wrong with people? Was the ER that bad?!
0 · Reply
Jblack500
Jblack500 May. 8 at 11:59 AM
$ANIP $ABVX $ARWR $GILD $ELAN anip earnings were excellent
0 · Reply
Latest News on ARWR
Arrowhead price target raised to $90 from $80 at Chardan

2026-05-08T08:35:40.000Z - 1 day ago

Arrowhead price target raised to $90 from $80 at Chardan

Arrowhead reports Q2 EPS (93c), consensus ($1.11)

2026-05-07T21:01:13.000Z - 2 days ago

Arrowhead reports Q2 EPS (93c), consensus ($1.11)

Arrowhead Pharmaceuticals Earnings Call Transcript: Q2 2026

May 7, 2026, 4:30 PM EDT - 2 days ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q2 2026

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

May 7, 2026, 4:01 PM EDT - 2 days ago

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma

2026-05-05T12:17:38.000Z - 4 days ago

Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma

MDGL

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

May 5, 2026, 8:00 AM EDT - 4 days ago

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

MDGL

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

May 4, 2026, 7:30 AM EDT - 5 days ago

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

Arrowhead announces Australian TGA approved Redemplo for FCS

2026-05-01T11:47:46.000Z - 8 days ago

Arrowhead announces Australian TGA approved Redemplo for FCS

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

May 1, 2026, 7:30 AM EDT - 8 days ago

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

Arrowhead initiated with an Overweight at JPMorgan

2026-05-01T08:45:41.000Z - 8 days ago

Arrowhead initiated with an Overweight at JPMorgan

Arrowhead announces EMA recommended approval of Redemplo

2026-04-24T10:46:32.000Z - 15 days ago

Arrowhead announces EMA recommended approval of Redemplo

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

Apr 24, 2026, 6:39 AM EDT - 15 days ago

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains.

Apr 21, 2026, 10:04 AM EDT - 18 days ago

This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains.

Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley

2026-04-21T09:10:37.000Z - 18 days ago

Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

Apr 20, 2026, 4:01 PM EDT - 19 days ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

Arrowhead price target raised to $93 from $81 at BofA

2026-04-20T15:29:23.000Z - 19 days ago

Arrowhead price target raised to $93 from $81 at BofA

Arrowhead presents long-term efficacy, safety data for plozasiran

2026-03-29T16:00:33.000Z - 5 weeks ago

Arrowhead presents long-term efficacy, safety data for plozasiran

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo

Mar 28, 2026, 10:30 AM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo

Arrowhead price target lowered to $81 from $84 at BofA

2026-03-26T15:20:29.000Z - 6 weeks ago

Arrowhead price target lowered to $81 from $84 at BofA

IONS

Arrowhead Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 2:20 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Arrowhead Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:50 AM EST - 2 months ago

Arrowhead Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

Feb 24, 2026, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

Arrowhead price target lowered to $78 from $81 at Morgan Stanley

2026-02-06T15:40:15.000Z - 3 months ago

Arrowhead price target lowered to $78 from $81 at Morgan Stanley

Arrowhead Pharmaceuticals Earnings Call Transcript: Q1 2026

Feb 5, 2026, 4:30 PM EST - 3 months ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q1 2026

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Feb 5, 2026, 4:05 PM EST - 3 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

Feb 4, 2026, 6:15 PM EST - 3 months ago

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

ADT CIEN DAY DVAX OSW

Arrowhead to replace Ciena in S&P 400 at open on 2/9

2026-02-04T22:26:13.000Z - 3 months ago

Arrowhead to replace Ciena in S&P 400 at open on 2/9

CIEN

ADT Inc. to replace Arrowhead in S&P 600 at open on 2/9

2026-02-04T22:25:49.000Z - 3 months ago

ADT Inc. to replace Arrowhead in S&P 600 at open on 2/9

ADT

Arrowhead doses first patient in ARO-DIMER-PA trial

2026-01-27T12:45:29.000Z - 3 months ago

Arrowhead doses first patient in ARO-DIMER-PA trial

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Jan 27, 2026, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead price target raised to $101 from $61 at B. Riley

2026-01-22T13:27:58.000Z - 3 months ago

Arrowhead price target raised to $101 from $61 at B. Riley

Arrowhead price target raised to $100 from $85 at H.C. Wainwright

2026-01-21T14:50:15.000Z - 3 months ago

Arrowhead price target raised to $100 from $85 at H.C. Wainwright

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Jan 20, 2026, 4:30 PM EST - 3 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Arrowhead price target raised to $110 from $100 at Piper Sandler

2026-01-13T12:22:17.000Z - 4 months ago

Arrowhead price target raised to $110 from $100 at Piper Sandler

Arrowhead Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Jan 7, 2026, 11:05 PM EST - 4 months ago

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Jan 7, 2026, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Jan 6, 2026, 6:14 PM EST - 4 months ago

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Arrowhead Pharmaceuticals Transcript: Study Update

Jan 6, 2026, 11:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Transcript: Study Update

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Jan 6, 2026, 11:26 AM EST - 4 months ago

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Jan 6, 2026, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Jan 5, 2026, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Dec 23, 2025, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Dec 15, 2025, 4:30 PM EST - 5 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Dec 8, 2025, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 10:00 AM EST - 5 months ago

Arrowhead Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Arrowhead Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 10:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Dec 2, 2025, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Dec 1, 2025, 4:00 PM EST - 5 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Arrowhead Pharmaceuticals Earnings Call Transcript: Q4 2025

Nov 25, 2025, 4:30 PM EST - 5 months ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q4 2025

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Nov 25, 2025, 4:00 PM EST - 5 months ago

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Arrowhead Pharmaceuticals Transcript: TD Cowen Treatment Advancements in Obesity and Related Disorders Summit

Nov 24, 2025, 1:30 PM EST - 5 months ago

Arrowhead Pharmaceuticals Transcript: TD Cowen Treatment Advancements in Obesity and Related Disorders Summit

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Nov 24, 2025, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

SRPT

Arrowhead Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 6:00 AM EST - 6 months ago

Arrowhead Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Arrowhead Pharmaceuticals Transcript: Study Result

Nov 18, 2025, 1:30 PM EST - 6 months ago

Arrowhead Pharmaceuticals Transcript: Study Result

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Nov 18, 2025, 11:52 AM EST - 6 months ago

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

US FDA approves Arrowhead's genetic disorder drug

Nov 18, 2025, 11:21 AM EST - 6 months ago

US FDA approves Arrowhead's genetic disorder drug

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Nov 6, 2025, 4:30 PM EST - 6 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Nov 4, 2025, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Oct 21, 2025, 7:30 AM EDT - 7 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Oct 7, 2025, 7:30 AM EDT - 7 months ago

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Sep 11, 2025, 7:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Arrowhead Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 11:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Sep 10, 2025, 7:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 10:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Arrowhead Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 9:10 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Arrowhead Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 1:00 PM EDT - 8 months ago

Arrowhead Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

Sep 2, 2025, 8:13 AM EDT - 8 months ago

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

NVS

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Sep 2, 2025, 7:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Aug 27, 2025, 7:30 AM EDT - 9 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Aug 13, 2025, 4:10 PM EDT - 9 months ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals Earnings Call Transcript: Q3 2025

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q3 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Aug 7, 2025, 4:01 PM EDT - 9 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Aug 1, 2025, 6:30 AM EDT - 10 months ago

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Jul 28, 2025, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Jul 23, 2025, 8:00 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Jul 21, 2025, 4:01 PM EDT - 10 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Jul 8, 2025, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jun 23, 2025, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Arrowhead Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 2:00 PM EDT - 11 months ago

Arrowhead Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Arrowhead Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 9:20 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Jun 2, 2025, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 29, 2025, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

Arrowhead Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 2:35 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2025

Arrowhead Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 2:20 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

Arrowhead Pharmaceuticals Earnings Call Transcript: Q2 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Earnings Call Transcript: Q2 2025

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 12, 2025, 4:01 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

May 7, 2025, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Apr 30, 2025, 4:01 PM EDT - 1 year ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

newarray
newarray May. 9 at 4:47 AM
$ARWR it's used to be 12% down-er I am glad mm can't shake more
0 · Reply
StockingStuffer2832
StockingStuffer2832 May. 8 at 8:20 PM
$ARWR probably under$70 for next weeks OpEx methinks. Got a lot of calls to knock out.
0 · Reply
skeezbag
skeezbag May. 8 at 5:26 PM
$ARWR mm just doing whatever they fucking want today. No consequences so wtf not
1 · Reply
Jblack500
Jblack500 May. 8 at 3:59 PM
$ANIP $GILD $ELAN $ARWR $ABVX who bought the dip..I know I did...current pt is near 110 and will see pt increases on this q and guidance
0 · Reply
stockhunter45
stockhunter45 May. 8 at 3:17 PM
$ARWR I think algos are dropping it on the earnings loss and once people with common sense understand at this point those numbers are not that significant this will go back up
0 · Reply
CDMO
CDMO May. 8 at 3:13 PM
$ARWR crazy swings
0 · Reply
Jblack500
Jblack500 May. 8 at 1:55 PM
$ANIP $GILD $ELAN $ARWR $ABVX anip pullback on these earnings is a gift and should be bought
0 · Reply
skeezbag
skeezbag May. 8 at 1:48 PM
$ARWR mm can go fuck themselves. This was set up yesterday with the bogus AH bid ask
0 · Reply
BiodegradableBurger
BiodegradableBurger May. 8 at 12:57 PM
$ARWR Wtf is wrong with people? Was the ER that bad?!
0 · Reply
Jblack500
Jblack500 May. 8 at 11:59 AM
$ANIP $ABVX $ARWR $GILD $ELAN anip earnings were excellent
0 · Reply
Sareptaking
Sareptaking May. 8 at 12:48 AM
$SRPT would be really nice to still have those $ARWR shares …
3 · Reply
SBL71
SBL71 May. 7 at 9:16 PM
$ARWR who the fk is on the line for Mani.... it's like the junior to the junior --lol...
1 · Reply
simonsp
simonsp May. 7 at 8:57 PM
$ARWR This Biotech Bi@tch will literally print money for the next 4-7 years.
0 · Reply
Wolfman5960
Wolfman5960 May. 7 at 8:18 PM
$ARWR Looks like they lowered the wholesale acquisition cost (WAC) of REDEMPLO to $45,000 per patient per year from the initial $60,000 price to better compete with Ionis Tryngolza's price of $40,000.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 7 at 8:09 PM
$ARWR Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.93 down -133.45% YoY • Reported revenue of $73.74M down -86.41% YoY • Arrowhead Pharmaceuticals Inc. expects to receive the second installment of an annual fee of up to $50M from Sarepta over the 12 months from March 31, 2026. Additionally, Arrowhead Pharmaceuticals Inc. is eligible for up to $975M in milestone payments from Madrigal.
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments May. 7 at 8:08 PM
$ARWR Posted... Redemplo, WAC $45K cost per patient per year Total prescriptions received and in process to date exceeds 400, representing greater than 40% growth over just the last four weeks alone; A total of approximately 180 patients to date have received at least one pre-filled syringe shipment; New weekly prescriptions are accelerating - currently averaging approximately 30 new written prescriptions per week; Approximately 85% of prescriptions were for patients naive to the APOC3 class — a strong signal that physicians are identifying and treating patients with FCS who have never had access to an effective therapy. Patients switching from other APOC3 targeted therapies largely account for the remainder; https://arrowheadpharma.com/en-us/newsroom/arrowhead-pharmaceuticals-reports-fiscal-2026-second-quarter
0 · Reply
Lolobel
Lolobel May. 7 at 8:06 PM
$ARWR 🤞🤞🤞🤞
0 · Reply
Pantherfan7979
Pantherfan7979 May. 7 at 7:24 PM
$ARWR
0 · Reply
superdog
superdog May. 7 at 3:56 PM
$ARWR
0 · Reply
BiodegradableBurger
BiodegradableBurger May. 7 at 3:03 PM
$ARWR Above $80 AH.
0 · Reply
skeezbag
skeezbag May. 7 at 2:26 PM
$ARWR nvidia is up so short biotech
0 · Reply
Lambrusco
Lambrusco May. 7 at 1:54 PM
$ARWR I believe Takeda initiated Phase 3 with Fazirsiran a number of months ago. Is that correct? Has Arrowhead earned a milestone payment? Just wonderong in advance of the Earnings Call.
1 · Reply